Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Review, H1 2016

  • ID: 3802754
  • Report
  • 60 pages
  • Global Markets Direct
1 of 5
Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Review, H1 2016

Summary

‘Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein)
- The report reviews Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics and enlists all their major and minor projects
- The report assesses Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Report Coverage

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Overview

Therapeutics Development

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Stage of Development

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Therapy Area

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Indication

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Companies

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Products under Development by Universities/Institutes

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Companies Involved in Therapeutics Development

Galectin Therapeutics, Inc.

PepTx, Inc.

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Drug Profiles

CNC-225 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-CT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Galectin-1 for B-Cell Non-Hodgkin Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTX-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate Gal-1 for Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Dormant Projects

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Discontinued Products

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) - Featured News & Press Releases

Jun 02, 2016: Galectin Therapeutics Announces Positive Preclinical Results on the Role of Galectin-3 in Mediating Vascular Remodeling in Pulmonary Arterial Hypertension

May 16, 2016: Galectin Therapeutics Announces Positive Interim Results from Phase 2a Trial with GR-MD-02 in Moderate-to-Severe Plaque Psoriasis

May 11, 2016: Galectin Therapeutics Announces Complete Enrollment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Advanced Fibrosis

May 05, 2016: Preclinical Research on the Role of Galectin-3 in Pulmonary Arterial Hypertension to be Presented at the American Thoracic Society 2016 International Conference

Feb 24, 2016: Galectin Therapeutics Receives U.S. Patent Allowance for GR-MD-02 to Treat Pulmonary Fibrosis

Jan 07, 2016: Galectin Therapeutics Posts "2015-2016, Progress and Possibilities" to Corporate Website

Nov 11, 2015: Research Underlying Galectin's Development of GR-MD-02 in Cancer Presented at the Society for Immunotherapy of Cancer Annual Meeting

Oct 19, 2015: Galectin Therapeutics' GR-MD-02 to be Studied in Combination With Keytruda in Patients With Metastatic Melanoma

Sep 24, 2015: Galectin Therapeutics Begins Phase 2a Psoriasis Study With GR-MD-02

Sep 16, 2015: Galectin Therapeutics Announces Start of Phase 2 Clinical Trial With GR-MD-02 in NASH With Advanced Fibrosis

Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases

Aug 03, 2015: Exalenz Bioscience Announces Collaboration with Galectin Therapeutics to use BreathID to Monitor Patients with Cirrhosis Associated with NASH

Jun 29, 2015: Galectin Therapeutics Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in NASH with Cirrhosis

May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam

Mar 24, 2015: Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry Colloquium

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 60List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Galectin Therapeutics, Inc., H1 2016

Pipeline by PepTx, Inc., H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016 45List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by Companies and remaining by the Universities/Institutes. The author's latest report Galectin-1 - Pipeline Review, H1 2016, outlays comprehensive information on the Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) Galectin-1 is a protein encoded by the LGALS1 gene. Galectin-1 binds to beta-galactoside. It plays an important role in regulating apoptosis, cell proliferation and cell differentiation. It inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase. It is a strong inducer of T-cell apoptosis. The molecules developed by Companies in Phase II and Preclinical stages are 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Furthermore, this report also reviews key players involved in Galectin-1 (Gal-1 or Lactose-Binding Lectin 1 or 14 kDa Laminin-Binding Protein) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Galectin Therapeutics, Inc.
PepTx, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll